Klaria Pharma Holding AB
The answer first
Does Klaria Pharma Holding beat the market?
No, Klaria Pharma Holding has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 1% of Nordic stocks
- Quality5
- Value0
- Trend17
No. 193 of 195 in healthcare
Max for seven days
Follow Klaria Pharma Holding with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Klaria Pharma Holding
Your first answer is free, no account needed.
Do you own Klaria Pharma Holding, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Klaria Pharma Holding and a few more. Free, no card.
Super Stock+46.4%In short
- Klaria Pharma Holding has fallen 7.3% over the past year, including dividends.
- Overall, Klaria Pharma Holding ranks better than 1% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 98.5%. The price is 96.7% below its peak now.
What do analysts think of Klaria Pharma Holding?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 1% of Nordic stocks.
No. 193 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 189 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity−0.04
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−115.2%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 195 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equitynegative earnings
- P/SPrice divided by sales964.1
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 134 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−54.6%
- 6 months−35.8%
- 9 months−31.7%
- 12 months−7.3%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Klaria Pharma Holding
One fund we follow owns Klaria Pharma Holding. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Klaria Pharma Holding
Klaria Pharma Holding AB is a company in healthcare, listed on Nasdaq Stockholm. By market value, Klaria Pharma Holding is number 83 of 137 companies in healthcare on Nasdaq Stockholm. Klaria Pharma Holding has not paid a dividend in the past twelve months. Of the three measures in the ranking, Klaria Pharma Holding is strongest on trend, better than 17% of Nordic stocks. The share trades in SEK. It has around 4 employees.
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. The company also offers Sirolimus which is in pre-clinical stage for prevention of organ transplant rejection. In addition, it is involved in commercialization and sale of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is based in Uppsala, Sweden.


See the full analysis of Klaria Pharma Holding.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card